LexaGene closes C$2.8M private placement

LexaGene said that it has closed an oversubscribed private placement, grossing C$2.8 million ($2.1 million).

LexaGene said it intends to use the proceeds of the transaction to fund beta development of its LX Analyzer technology, which uses microfluidic PCR for pathogen detection, and for marketing the technology to the food safety and veterinary diagnostics industries.

Source: https://www.genomeweb.com/

Related presentations

Login to access our presentations

Liked this post?

Share it on your social networks